EV Biologics is now Pink Current

Rhea-AI Summary

EV Biologics Corp (OTC PINK:YECO) has announced its compliance with OTC Markets, achieving a Pink Current status, which enhances trading accessibility for brokers. CEO Daniel Mckinney expressed satisfaction with this development as the company shifts focus towards innovative regenerative biologics, targeting a secured funding of up to $5 million for new exosome-related projects. Additionally, EV Biologics plans to apply for a name change and intends to up-list to OTCQX by year-end.

Exosomes are highlighted for their therapeutic potential in treating various diseases, including cancer.

Positive

• Achieved Pink Current status, enhancing trading accessibility.
• Secured funding of up to $5 million for regenerative biologics development.
• Plans to apply for a name change and up-list to OTCQX by year-end.

Negative

• None.

CHEYENNE, WY / ACCESSWIRE / June 14, 2021 / EV Biologics Corp (OTC PINK:YECO) today announced that it has completed all its filings on OTC Markets and is now Pink Current.

Being current and Penny Stock Exempt allows the majority of brokers to trade in our stock.

CEO Daniel Mckinney, said 'we are pleased to be current in our filings and are now focused on developing innovative regenerative biologics including engineered exosomes and other stem cell-derived products. We will be utilizing our secured funding of up to $5 million to begin generation of a novel exosome-producer cell line and production of therapeutic extracellular vesicles and nanoparticles for preclinical research.'

As reported on May 19^th, the Company has submitted an application to FINRA to change its name and trading symbol.

EV Biologics is building a world-class team of exosome biotechnology experts specializing in molecular biology, biochemical engineering, biomanufacturing, cellular biochemistry, bioinformatics and computational biology.

Please visit our website: www.evbiologics.com

EV was previously a Nasdaq listed company and intends to apply to up-list to OTCQX before the end of 2021.

Exosomes

Exosomes are nano-sized vesicles that serve as mediators for cell-to-cell communication. With their unique nucleic acids, proteins, and lipids cargo compositions that reflect the characteristics of producer cells, exosomes can be utilized as cell-free therapeutics. - Cells, 2020

The intrinsic properties of exosomes in regulating complex intracellular pathways has advanced their potential utility in the therapeutic control of many diseases, including neurodegenerative conditions and cancer. Exosomes can be engineered to deliver diverse therapeutic payloads, including short interfering RNAs, antisense oligonucleotides, chemotherapeutic agents, and immune modulators, with an ability to direct their delivery to a desired target. - Science, 2020

About the Company

EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on developing and enhancing the intrinsic therapeutic activity of mesenchymal stromal cell (MSC) secreted factors as well as targeted delivery of bioactive molecules using engineered exosomes. The company is working to optimize cell lines for production of native bioactive nanoparticles and to establish an exosome engineering platform to enhance specific therapeutic activity. Initially, these novel regenerative products will be produced for preclinical research on a number of clinical indications. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in these bioengineered products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.

Forward-Looking Statements

This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases 'plans,' 'would be,' 'will allow,' 'intends to,' 'may result,' 'are expected to,' 'will continue,' 'anticipates,' 'expects,' 'estimate,' 'project,' 'indicate,' 'could,' 'potentially,' 'should,' 'believe,' 'think,' 'considers' or similar expressions are intended to identify 'forward-looking statements.' These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

YECO has 7.225 million shares issued and outstanding with a float of 1,016,375 shares.

Contact:

Dennis Burns
Investor Relations
Tel(567)237-4132
dburns@nvestrain.com

For more information on EV Biologics please visit:

www.evbiologics.com

SOURCE: EV Biologics Corporation

View source version on accesswire.com:
https://www.accesswire.com/651597/EV-Biologics-is-now-Pink-Current

FAQ

What is the significance of EV Biologics achieving Pink Current status on June 14, 2021?

Achieving Pink Current status allows EV Biologics to be more accessible for brokers to trade their stock, potentially increasing investor interest.

How much funding has EV Biologics secured for its regenerative biologics projects?

EV Biologics has secured up to $5 million for developing innovative regenerative biologics, including engineered exosomes.

What are exosomes and their significance in EV Biologics' research?

Exosomes are nano-sized vesicles that facilitate cell-to-cell communication and have potential therapeutic uses, which EV Biologics aims to exploit in treating diseases.

When does EV Biologics plan to apply for an up-list to OTCQX?

EV Biologics intends to apply for an up-list to OTCQX before the end of 2021.